A new prenatal roadmap could soon help clinicians place endotracheal tubes (ETTs) more precisely in the tiniest preterm newborns. In infants with birth weights under 500 g, even small positioning errors during intubation can increase the risk of life‑threatening complications, including inadequate ventilation or airway trauma. Researchers say their approach uses measurements taken before birth—capturing the baby’s anatomy while it is still developing in utero.

The study focuses on predicting the optimal ETT depth rather than relying solely on standard postnatal formulas. Using prenatal biometry, investigators model how fetal growth and structural proportions relate to the distance from the mouth to the trachea. The goal is to translate ultrasound-derived anatomical signals into a practical estimate that can guide clinicians at the bedside.

Technically, the model links prenatal measurements to the anticipated airway dimensions at delivery. This requires defining which biometric inputs best correlate with the final tube placement target, then training a predictive framework to output a recommended insertion depth for extremely low birth weight infants. By emphasizing prenatal inputs, the method aims to reduce uncertainty that can arise from day-to-day postnatal changes.

Importantly, the research targets a subgroup with particularly high vulnerability. Infants below 500 g are at increased risk because their airway structures are extremely small and intubation margins are narrow. In this context, individualized prediction could improve consistency compared with one-size-fits-all guidelines.

If validated in larger clinical settings, the prenatal model could be integrated into obstetric and neonatal workflows. After routine prenatal ultrasound assessments, clinicians would generate an ETT depth estimate ahead of delivery, supporting more confident planning for immediate respiratory care.

The findings also highlight a broader trend in perinatal medicine: using quantitative prenatal data to optimize invasive procedures. Instead of reacting after intubation placement, the strategy moves decision-making earlier—toward anticipation, personalization, and safety.

Overall, the work suggests that prenatal biometry can carry actionable information for airway management. The team frames the approach as a step toward more precise, data-driven neonatal resuscitation and ventilation strategies for the smallest patients.

The study, published in Journal of Perinatology, is available under DOI: 10.1038/s41372-026-02851-2.

Subject of Research: Prenatal biometry-based prediction of optimal ETT depth
Article Title: Prenatal biometry-based prediction of optimal endotracheal tube depth in infants with a birth weight less than 500 g.
Article References: Yoo, K., Kim, S.H., Park, J. et al. J Perinatol (2026). https://doi.org/10.1038/s41372-026-02851-2
Image Credits: AI Generated
DOI: 10.1038/s41372-026-02851-2
Keywords:

Short-chain fatty acids (SCFAs)—especially acetate, propionate, and butyrate—are produced when gut microbes ferment carbohydrates that the human body cannot digest. Over the past decade, these small molecules have moved beyond being viewed as simple fuel. Instead, they are now recognized as signalling messengers that help tune metabolism, shape immune responses, and support physiological balance across organs. A new review in Nature Metabolism brings together scattered findings to clarify how SCFAs are made, how they are processed in the body, and why they matter for health.

The article emphasizes that SCFA production is not uniform. It depends on which microbial communities inhabit the gut, which dietary substrates reach the colon, and how microbes share resources through cross-feeding. When multiple bacterial species coordinate, fermentation pathways can shift, increasing the output of particular SCFAs. In that way, the “hardware” of the microbiome and the “inputs” provided by diet jointly determine the chemical signals generated in the intestine.

After their formation, SCFAs are handled by host tissues through absorption and further metabolic conversion. The review highlights that acetate, propionate, and butyrate can influence local and systemic physiology, helping link intestinal chemistry to whole-body regulation. Their effects are therefore both immediate—through signalling pathways—and longer-lasting—through changes in gene regulation.

Mechanistically, the authors focus on receptor-mediated communication. SCFAs activate specific receptors on immune and metabolic cells, altering inflammatory tone and metabolic signalling. This receptor layer helps explain how intestinal events can reverberate in distant tissues that rely on tightly controlled energy and immune states.

Beyond receptors, SCFAs also affect epigenetics. By influencing chromatin-modifying enzymes and related regulatory networks, they can change how genes are expressed without altering DNA sequence. Such effects provide a plausible bridge between diet–microbiome interactions and sustained shifts in health trajectories.

The review further surveys tissue-specific outcomes, from effects on gut barrier function to immune regulation and metabolic homeostasis. Importantly, this heterogeneity helps reconcile why SCFAs sometimes show protective associations while other contexts yield mixed results—differences in dose, timing, microbial ecology, and host physiology can all matter.

When the evidence is assembled, the paper argues that SCFAs are strongly implicated in metabolic health and disease risk. Conditions such as obesity, insulin dysregulation, and inflammatory disorders have been linked to altered SCFA profiles, though causality remains an active area of investigation. The authors also discuss the limitations of current studies, including differences in measurement methods and confounding dietary factors.

Finally, the review evaluates translational opportunities. Rather than treating SCFAs as isolated supplements, it frames dietary and therapeutic strategies around pathways that enhance beneficial SCFA production or mimic their downstream effects. With low fibre intake becoming a public health concern worldwide, the work positions SCFAs as a key biological rationale for improving diet quality.

Overall, this Nature Metabolism review synthesizes what is known—and what is still uncertain—about SCFAs as central mediators between gut microbes and host biology. It suggests that targeting microbial fermentation and SCFA signalling could become a practical lever for metabolic disease prevention.

Subject of Research: Gut microbiota–derived short-chain fatty acids and their physiological roles
Article Title: Short-chain fatty acids
Article References: Dagbasi, A., Cai, M., Hirdaramani, A. et al. Short-chain fatty acids. Nat Metab (2026). https://doi.org/10.1038/s42255-026-01579-9
DOI: https://doi.org/10.1038/s42255-026-01579-9
Image Credits: AI Generated

Age-related remodeling of the immune system leaves older adults increasingly susceptible to sudden infections and cancer, while also promoting chronic, misdirected inflammation and impaired wound repair. These effects help drive a wide spectrum of long-term diseases. Yet despite rapid progress in immunology and gerontology, key mechanistic links—how specific immune-cell programs degrade over time and how that degradation shapes early response decisions—remain incompletely understood.

A major obstacle has been the limited availability of immune-aging models that are both predictive and experimentally tractable. Conventional in vitro systems often fail to capture the tissue context, cellular crosstalk, and microenvironmental cues that govern when and how immune responses ignite. As a result, “aging phenotypes” can be difficult to reproduce across laboratories and difficult to connect to causal pathways.

In a 2026 Nature Aging discussion, Nikolich and colleagues argue that the field needs a shift from descriptive comparisons toward engineered, mechanistically grounded platforms. They propose multidisciplinary strategies spanning immunology, gerontology, and engineering to interrogate immune aging at the point of initiation—when innate sensors, tissue barriers, and early signaling networks collectively determine the trajectory of downstream immunity.

The authors highlight drug delivery technologies as a route to more precise interventions. By tuning where, when, and at what dose immunomodulatory agents act, researchers could better test how age-altered signaling thresholds change the balance between protective responses and harmful inflammation.

They also emphasize extracellular matrix (ECM) and biomaterials, noting that aging reshapes the physical and biochemical scaffold surrounding immune cells. Biomaterials that recapitulate age-associated stiffness, ligand density, and degradation dynamics could reveal how microenvironmental cues reprogram immune recruitment, activation, and effector function.

Microphysiological systems and organoid-like models are presented as complementary engines for causality. These platforms can integrate multiple cell types, enable controlled perturbations, and better mimic tissue architecture than traditional culture formats.

Together, these approaches aim to deliver validated in vitro tools for immune-aging research—tools designed not only to measure differences, but to reproduce them reliably and connect them to specific upstream drivers.

The ultimate ambition is precision diagnostics and therapies that can “reprogram and rejuvenate” immune function in older adults, extending both lifespan and healthspan. By targeting immune-response initiation with engineered models, the field may finally bridge the gap between observational aging biology and interventions that work.

Subject of Research: Aging immune system; immune response initiation models and modulation

Article Title: Bioengineering strategies to interrogate and modulate the aging immune system

Article References: Nikolich, J.Ž., Wolf, M.T., Pompano, R.R. et al. Bioengineering strategies to interrogate and modulate the aging immune system. Nat Aging (2026). https://doi.org/10.1038/s43587-026-01187-y

Image Credits: AI Generated

DOI: https://doi.org/10.1038/s43587-026-01187-y

Glenview, Illinois—CHEST, the American College of Chest Physicians’ flagship journal portfolio, has reported a major milestone for its open-access publication CHEST® Critical Care: the journal has earned its first Journal Impact Factor of 2.7. Released annually by Clarivate through the Journal Citation Reports, the metric reflects the average number of citations received by articles published in a journal, serving as a widely used proxy for scholarly influence.

In practical terms, an Impact Factor offers more than prestige. It functions as a signal to authors, clinicians, and research teams that the work circulating in a journal is being engaged by the wider scientific and medical community—particularly important in time-sensitive domains like intensive care medicine, where findings can influence protocols and bedside decision-making.

Hayley Gershengorn, MD, FCCP, Editor in Chief of CHEST Critical Care, emphasized that the achievement is rooted in the ecosystem around the journal. Authors contribute original and reproducible studies; reviewers help refine rigor and clarity; editorial leadership maintains standards; and readers ensure the research travels beyond publication.

The journal was designed to accelerate dissemination of high-quality critical care research while keeping access frictionless. Because CHEST Critical Care is fully open access, its content can be read by practitioners, investigators, and policymakers worldwide without subscription barriers—an element that can broaden citation pathways and facilitate adoption of evidence-based practices.

Beyond original studies, the journal publishes a range of formats, including reviews and case reports, as well as “How I Do It” clinical education articles. This blend supports both scientific discovery and translational learning, which can be critical for managing complex syndromes such as sepsis, respiratory failure, and septic shock.

For biomedical audiences, open-access visibility plus peer-reviewed credibility creates a compelling combination: findings are discoverable, accessible, and citable. That coupling helps explain why emerging journals can gain momentum quickly when their content resonates with urgent clinical needs.

To follow updates across the CHEST journal ecosystem, readers can visit the CHEST website and track news via the journal’s social channels. The organization frames the Impact Factor as a validation of community effort—and as motivation to keep publishing research that improves outcomes in critical care.

Subject of Research: Critical care medicine; scholarly publishing metrics
Article Title: CHEST Critical Care Achieves First Journal Impact Factor of 2.7
News Publication Date: Not provided
Web References: https://www.chestnet.org/guidelines-and-topic-collections/publications ; https://www.twitter.com/journal_chest
References: Clarivate Journal Citation Reports (Journal Impact Factor methodology)
Image Credits: Not provided
Keywords: CHEST Critical Care, Journal Impact Factor, Clarivate, open access publishing, critical care medicine, citations, peer review, intensive care research

An eye implant that can help blind people see again is poised to hit the market — in Europe, at least.

On Wednesday, the US-based Science Corporation announced that it had received approval from the European Union to treat patients with its vision-restoring bionic eye device, called Prima, in a huge step towards the commercialization of the technology.

“We have a cochlear implant for vision now,” CEO Max Hodak told Stat News.

Science Corp’s device is designed to treat advanced macular degeneration, a condition in the eye which causes central vision loss. It’s the leading cause of vision loss in older adults, with severe forms of it accounting for nearly 90 percent of legal blindness in the US, according to one estimate.

To restore vision, the Prima device uses a wireless chip that’s surgically implanted under the retina. This connects with a pair of camera-equipped glasses, which transmits video in the form of near-infrared light that the chip turns into electrical signals interpreted by the brain.

Science Corp first published the results of a preliminary clinical trial in late 2024, showing that patients who used the device were able to recognize faces again, and even read books.

“One of our patients in France finished a 300-page novel a little while ago, and sent us the book,” Hodak recently told TechCrunch. “We have a sketch on the wall [that] one of our patients drew of the Sydney Opera House. There are videos of patients playing crossword puzzles and filling in Sudoku.”

But Hodak — who cofounded Neuralink with Elon Musk before leaving to start Science Corp — was candid that his tech still has a lot of room for improvement.

“This is an early version. It’s kind of like looking through a straw in the centre of their vision,” he told the Financial Times, saying it was “powerful proof” that the company was on the right track.

“We see in the future how to get to colour pretty close to native acuity,” he added.

Each Prima device is expected to cost hundreds of thousands of dollars, but Science Corp says it’s working with healthcare providers to cover some of the cost, per TechCrunch. It’s most likely to first start treating patients in Germany, where it conducted its clinical trials.

It’s not the only company making moves in this space. Neuralink is also working on a vision implant called Blindsight, but it hasn’t begun human trials yet.

More on health: Trump Is Having a Major Problem With Diarrhea

The post Eye Implant That Restores Vision to the Blind Cleared for Sale appeared first on Futurism.

A large Danish study found a modest but consistent association between long-term road traffic noise exposure and higher Parkinson's disease risk, with a 3% increase for every 11.5 dB rise in noise at the most exposed side of a home. The Guardian reports: The researchers modeled noise exposure at the most and least exposed exterior of the residence of each participant and calculated the difference in noise levels. The magnitude of the effect was modest but consistent; at the most exposed facade, for every 11.5dB rise in noise level, the risk of Parkinson's disease rose by 3% over the study period. Having a quiet part of the home may mitigate the association between exposure to road traffic noise and higher risk of Parkinson's disease, according to the findings. The study, published in Jama Neurology, included 3.1 million Danish participants aged 40 and over, and followed them for 18 years. It was established using nationwide health register data, making it the largest study on road traffic noise and Parkinson's disease. Previous research linked the rise in neurological disorders, including Parkinson's disease, with exposure to environmental toxins. Environmental risk factors such as air pollution, microplastics and pesticides have become the main focus of prevention strategies. The study is one of the first to make the link to noise pollution.

Read more of this story at Slashdot.

A PET radiotracer that can detect deep vein thrombosis (DVT) in the legs and clots that have travelled to the lungs has been chosen as the “Image of the Year” at the Society of Nuclear Medicine and Molecular Imaging (SNMMI) 2026 annual meeting. Developed by Sangwon Han and colleagues at the Asan Medical Center, University of Ulsan College of Medicine, in Korea, the novel tracer enables whole‑body imaging of blood clots (thrombi) in the legs and lungs in a single scan.

A DVT is a blood clot that forms in a deep vein, usually in the legs. It’s a common condition, with an incidence of roughly half that of all cancers, and it can lead to serious complications. Clots can break off and travel to the lungs, which could cause a potentially life‑threatening pulmonary embolism (a blockage in the artery supplying blood to the lungs). Early detection of DVT is therefore critical for determining the most appropriate treatment for each patient.

Currently, the standard imaging method for diagnosing DVT is venous ultrasonography (VUS). But while this works well for detecting clots in the thigh-to-knee region, whole-leg VUS requires skilled operators and advanced machines, takes longer, and has lower diagnostic sensitivity in the calf. In addition, conventional imaging techniques such as VUS and CT rely on indirect structural changes rather than directly visualizing the clot.

Aiming to enable faster and more efficient DVT diagnosis, Han and his research team are studying fluorinated GP1 (¹⁸F-GP1) a novel thrombus-targeted PET tracer. The tracer selectively binds to specific receptors on activated platelets (the cell fragments that cause blood to clots), allowing direct visualization of active thrombus formation.

“In our Phase 1 study, ¹⁸F-GP1 PET/CT showed 100% detection rate in 20 patients with confirmed DVT or pulmonary embolism,” Han told the SNMMI delegates. “But that study was limited by its small sample size and an absence of negative groups so specificity could not be assessed at that time.”

So in this latest work, Han and his team performed a phase 2, non-randomized study investigating the ability of ¹⁸F-GP1 PET/CT to identify acute lower-extremity DVT in 46 symptomatic patients. This included 22 patients with proximal DVT and 24 with none or distal DVT, as diagnosed using VUS.

The researchers acquired chest-to-feet PET/CT scans approximately 2 h after intravenous administration of 250 MBq of the radiotracer. The images were assessed by three blinded nuclear medicine physicians from different institutions, who assigned focal ¹⁸F-GP1 uptake higher than background activity as positive for thrombosis. They classified proximal DVT as clots involving the iliac (pelvic), femoral (thigh) and popliteal veins (behind the knee), and distal DVT as clots confined to the calf veins.

“Our primary objective was to assess the sensitivity and specificity of qualitive ¹⁸F-GP1 PET/CT interpretation for proximal DVT,” Han explained. “Secondary objectives included assessing the agreement between PET/CT and VUS for distal DVT, inter-reader reproducibility, exploring the detection of pulmonary embolism and assessing safety.”

When evaluated against VUS as a reference standard, ¹⁸F-GP1 PET/CT exhibited high diagnostic accuracy for detecting clots, demonstrating a sensitivity of 95% and a specificity of 92% for proximal DVT. “For distal DVT, both positive and negative agreement between PET/CT and VUS were strong,” added Han. “Inter-reader agreement was also excellent.”

The scans also identified concomitant pulmonary emboli in some patients, as confirmed by CT pulmonary angiography, illustrating the advantage of simultaneously assessing DVT and pulmonary embolism in a single scan. The researchers noted that the radiotracer was well tolerated, with no drug-related adverse events observed.

Speaking in the plenary session when his award was announced, Han shared a “striking image” recorded using ¹⁸F-GP1 PET/CT, which showed extensive blood clots, not only in the leg and lungs, but also in many unusual sites, including cranial and spinal vessels, cardiac valves, and vessels in the pelvic region. “This image clearly shows the remarkability ability of fluorinated GP1 to visualize thrombi throughout the body,” he explained.

“We believe this represents an important step towards thrombus-specific imaging,” Han concluded. “The potential of GP1 PET can expand beyond DVTs to many other thrombotic diseases such as embolic stroke or other cardiovascular diseases.”

The SNMMI Image of the Year is the society’s highest award, and the most anticipated, given out in recognition of an image that’s truly cutting-edge and representative of the future of nuclear medicine. This year’s winning image was chosen from nearly 1500 abstracts submitted for the meeting.

“It is truly a great honour to receive the Image of the Year award,” said Han.

 

The post PET scan that detects dangerous blood clots is SNMMI ‘Image of the Year’ appeared first on Physics World.

As AI reshapes the way we communicate, researchers at Texas A&M University are developing an artificial intelligence-powered platform that could transform care for children with autism and older adults living with dementia. The technology learns each person’s unique communication style, behaviors, and preferences, enabling increasingly personalized support for caregivers, therapists, and families over time.

Called VoiceLove, it is one of three projects being developed with support from the Advanced Research Projects Agency for Health (ARPA-H).

At the core of the system is an AI engine that analyzes both speech and nonverbal behaviors documented through short videos recorded by caregivers or therapists during daily communications and interactions. Rather than comparing participants against a general model, the platform focuses on understanding each person’s individual patterns and communication style.

“Every child with autism is unique, and effective support should reflect that,” he said. “Our project leverages artificial intelligence to understand each child’s individual behaviors, communication styles, and preferences. The goal is to deliver personalized recommendations that help families, educators, and clinicians work together more effectively, enabling more responsive, data-driven care and improving the health and well-being of children with autism,” says Dr. Junhyoung Kim, associate professor in the School of Public Health, one of the principal investigators on the project, in a statement. 

The AI system was created to identify behavioral patterns in communication, interests, and responses across different situations. Based on its observations, the program provides personalized recommendations that could help therapists or caregivers create individualized intervention plans.

“The key innovation behind this platform is its ability to understand each child individually and learn their unique preferences, needs, communication styles, and strengths to deliver personalized recommendations,” Kim said. “For people living with dementia, the platform is designed to enhance person-centered care by helping residents communicate their needs, preferences, and daily experiences more effectively.”

Researchers say the technology could support a wide range of developmental goals, including improving communication skills, encouraging self-care, strengthening social engagement, and enhancing a person’s quality of life.

The same personalized approach could also benefit people living with dementia, where communication challenges often make it difficult for individuals to express their needs and wants. 

“Our vision is to create an AI platform that continuously learns from each child’s daily experiences,” Kim said. “As the system identifies patterns in behaviors, preferences, and responses to different activities, it can provide therapists and caregivers with personalized recommendations that evolve over time.”

“This adaptive approach helps explain why certain behaviors occur and supports more individualized, proactive care,” Kim added. 

VoiceLove is designed to keep learning. As caregivers continue using the app, the AI analyzes new interactions while also incorporating caregiver observations, experiences, and responses to daily prompts. 

The research team plans to begin with a small pilot study involving children with autism and older adults living with dementia after receiving Institutional Review Board approval.

Participants will use the platform for approximately one month while researchers evaluate its usability, feasibility, and overall user experience, and from there, insights derived from the pilot will help to inform a larger-scale study at some point in the future. 

Chrissy Newton is a PR professional and the founder of VOCAB Communications. She currently appears on The Discovery Channel and Max and hosts the Rebelliously Curious podcast, which can be found on YouTube and on all audio podcast streaming platforms. Follow her on X: @ChrissyNewton, Instagram: @BeingChrissyNewton, and chrissynewton.com. To contact Chrissy with a story, please email chrissy @ thedebrief.org.

Researchers, including those from the University of Tokyo, found a way to optimize how cells bind to small packages they release called extracellular vesicles. By coating the vesicles with metal ions, they made cells and their corresponding vesicles stick together more strongly than they would naturally. This reduced the time needed for cells to capture their own vesicles, even in mixtures containing billions of other vesicles.

Jackie found an online audience through a webcam pointed at her nest in California. She was rescued last week after a fight with other eagles, officials said.

Un'analisi condotta dalla University of Pennsylvania su 12.000 pazienti affetti da diabete di tipo 2 e pubblicata su The BMJ ha rilevato che i farmaci agonisti del GLP-1 (come semaglutide e tirzepatide) comportano un rischio leggermente maggiore di caduta dei capelli rispetto ad altri antidiabetici. I pazienti in terapia con GLP-1 mostrano un rischio superiore del 37% rispetto a chi assume inibitori SGLT-2 e del 68% rispetto a chi usa inibitori DPP-4. L'incidenza reale resta comunque ridotta (1,6% dei casi) e riguarda forme di alopecia non cicatriziale: il fenomeno è in gran parte reversibile ed è causato dallo stress metabolico del rapido dimagrimento e da potenziali carenze nutrizionali.

President Donald Trump has a major problem with explosive diarrhea on his hands.

On Tuesday, HHS secretary Robert Kennedy Jr declared that the ongoing outbreak of cyclosporiasis — a non-lethal but extremely unpleasant gut infection caused by the Cyclospora cayetanensis parasite — was “under control.”

“We’ve identified the source of the outbreak, and the companies that are involved have implemented a recall,” he said, without elaborating any further or naming the companies.

But considering that cases are still rising, the situation is very much not looking under control. According to a Tuesday update by the Centers for Disease Control and Prevention, there have been 4,173 laboratory-confirmed domestic cases of cyclosporiasis since May 1. There are an additional 7,400 cases that have yet to be confirmed, many of which were reported in Michigan and Ohio.

Those tallies appear to be underestimating the scale of the problem considerably. In Michigan alone, state officials warned on Wednesday that there were 7,171 cyclosporiasis cases since June 22, up from 6,571 on July 21, suggesting the outbreak is only getting started.

Cases reported by the Ohio Department of Health tripled to 1,192 cases in its July 16 update, compared to June 20 — another sign that the situation is getting worse, not better.

And that’s just the data we know about. Identifying the parasite is notoriously difficult in a lab, making it particularly difficult to trace, and requiring extensive detective work by health officials.

Yet the public messaging regarding news about the outbreak has been severely lacking and downright confusing. Over the same weekend, the Food and Drug Administration said it had determined the culprit, bagged shredded lettuce ⁠supplied by Taylor Farms, one of Taco Bell’s lead suppliers — only to claim that the results were a “false positive” less than a day later.

Taylor Farms, which continues to “voluntarily” recall its tainted lettuce, celebrated the update, claiming the FDA had “apologized to us” in a since-deleted Monday statement.

Just hours later, the situation flipped on its head once again, with the FDA saying that “FDA’s traceback investigation and outbreak data continue to converge on shredded iceberg lettuce from Taylor Farms locations in central Mexico.”

There are plenty of reasons to be highly skeptical of the government narrative. The Trump administration maintains a cozy relationship with Taylor Farms, a company that has made a major donation to Trump’s political action committee, MAGA Inc.

The White House has since vehemently denied accusations from the media that it may be colluding with Taylor Farms behind the scenes, with the Health and Human Services Department calling them “FAKE NEWS” in a Monday statement — the kind of knee-jerk reaction that’s bound to invite even more scrutiny.

Then there’s the Trump administration’s gutting of key public health programs that could make truly getting the cyclosporiasis outbreak under control. Budget cuts have led to massive layoffs at the USDA, CDC, and FDA. Key food inspection and surveillance programs ahve been terminated. A team specifically dedicated to tracking cyclospora was slashed by Elon Musk’s so-called Department of Government Efficiency last year from 11 to just three people.

In short, while Kennedy claims the situation is under control, there’s plenty of evidence to the contrary. Cases are on the rise and even the evidence behind FDA’s leading suspect appears to be shaky, by the agency’s own admission.

It’s the perfect storm of short-sighted austerity measures, chummy business relationships, and poor public messaging by officials who are unable to speak from a place of authority and conviction.

Put simply, Trump’s diarrhea troubles are likely only getting started.

More on the outbreak: Trump’s Explosive Diarrhea Scandal Is Getting Worse and Worse

The post Trump Is Having a Major Problem With Diarrhea appeared first on Futurism.

The U.S. hasn't seen measles numbers like this since 1992. An epidemiologist explains what's driving the surge.

There’s something undeniably fishy about the Trump administration’s handling of the rising outbreak of an explosive diarrhea-causing parasite — and we’re not talking about tainted iceberg lettuce.

On Saturday, the FDA announced that it had found traces of the Cyclospora cayetanensis parasite — which more than likely won’t kill you, but will almost certainly cause weeks of violent diarrhea — in samples of bagged shredded lettuce ⁠supplied by Taylor Farms, one of Taco Bell’s lead suppliers.

One day later, the agency suddenly reversed its decision, announcing that its test results were a false positive, seemingly exonerating Taylor Farms. The company is still carrying out a voluntary recall of the offending greens, a move first announced on Friday.

The unexpected twists and turns of the devastating outbreak highlight how the Trump administration is struggling to get coherent messaging out to the American people, a public health disaster facilitated by massive health budget cuts and major layoffs at the FDA, USDA, and CDC. We still don’t know exactly how many people are affected, numbers that vary wildly depending on whether you ask the CDC or individual states. It’s a confounding mess, compounded by the fact that the parasite is notoriously difficult to trace in a lab.

There are plenty of reasons to be suspicious of the FDA’s baffling reversal on Sunday. For one, the Trump administration’s relationship with the embattled food supplier goes way back. Case in point, Taylor Farms made a mysterious $1 million donation to the Trump-aligned super PAC MAGA Inc on March 26, 2025, as first spotted by lawyer and public health policy leader Matthew Cortland — six days before the FDA loosened food traceability rules which could’ve helped prevent outbreaks like the current one.

The company appears to have considerable sway in Washington, DC. On July 17, a day before the FDA announced it had found traces of the parasite, the New York Times reported that Taylor Farms representatives had met with White House and FDA officials the day before to discuss what the company viewed as “shortfalls in the FDA and CDC’s outbreak response process.”

While it’s unclear whether the supplier successfully strong-armed the FDA into going back on its initial claims of having found traces of the parasite, the timelines are certainly suspect. According to the NYT, Taylor Farms had also hired lobbyist Trent Morse, who served as the deputy director of the White House Presidential Personnel Office before he resigned in September.

The story only gets stranger after the FDA issued its mea culpa. In the early morning hours of Monday, Taylor Farms published an “update” — which has since been deleted for an unknown reason — claiming that the FDA had “apologized to us” while trying to reassure customers that “all other Taylor Farms products… are not involved in the recall.”

Less than 12 hours later, the FDA once again pulled a 180.

“To clarify, this false-positive lab sample DOES NOT change the basis for FDA’s ongoing outbreak investigation or the overwhelming epidemiological data supporting the current voluntary recall by Taylor Farms,” the agency tweeted on Monday.

“FDA’s traceback investigation and outbreak data continue to converge on shredded iceberg lettuce from Taylor Farms locations in central Mexico,” the statement reads. “FDA will continue to work with federal and state partners to investigate this multistate outbreak and ensure products implicated in this outbreak have been removed from the market.”

It’s hard to rule out that White House officials were trying to vindicate Taylor Farms, considering the Trump administration has long been accused of giving major MAGA Inc donors favorable “pay for access” treatment. Taylor Farms’ willingness to recall the lettuce alone speaks volumes.

Naturally, the White House is now accusing the media of putting far too much of a spin on the story.

“This is how the FAKE NEWS works: imply collusion, ignore the facts,” the Health and Human Services Department, which oversees the FDA, tweeted on Monday, replying to reporting by Meidas Touch about Taylor Farms’ PAC donation. “Nothing influences our decisions except science and the safety of the American people.”

By Tuesday, the White House had already declared victory, with HHS secretary and notorious anti-vaccine activist Robert Kennedy Jr claiming that the outbreak was “under control.” He vaguely referred to “companies that are involved,” which had “implemented a recall” — but never mentioned Taylor Farms by name.

We’ll leave it up to you whether that’s reassuring enough to pick up a heavily discounted pack of shredded iceberg lettuce at the local Whole Foods. As of Tuesday, Michigan alone is dealing with over 6,500 cases.

More on the saga: Taylor Farms Made Huge Donation to Trump Group After Loosening of Rules That Could Have Prevented Explosive Diarrhea Outbreak

The post Trump’s Explosive Diarrhea Scandal Is Getting Worse and Worse appeared first on Futurism.

Shigella causes about 450,000 U.S. infections each year. An experimental oral vaccine protected adults in a small human trial.

Most of the nation may want nothing to do with Taylor Farms and its shredded iceberg lettuce, which was recalled in dozens of states for potentially being contaminated with a parasite that turns your bowels into a garden hose.

Not so for the Amazon-owned Whole Foods, which is either hoping to capitalize on the controversy or proceeding as if nothing happened. 

Over the weekend, we noticed that one of the grocery retailer’s locations in New York City was selling Taylor Farms’ shredded iceberg at a steep 50 percent discount — which, from an optics point of view, is absolutely extraordinary.

Is this an indictment of our country’s ruthless opportunism, and by extension, capitalism at large? Is it a total nonstory? If you’re unlucky enough, you’ll have plenty of time to ponder those questions on the porcelain throne. Many on social media just seemed to think it was a mix of funny and appalling.

“The cost is on the back end,” someone joked. “Discount diarrhea,” chimed another. Others were outraged that the location was still selling the stuff.

“They’re seriously not pulling that off the shelf,” one fumed. “For SHAME.”

wow at this incredible deal

— jon christian (@jonchristian.net) 2026-07-19T19:15:11.425Z

The Food and Drug Administration narrowed the culprit down to a Taylor Farms facility in Mexico. So far, Taylor Farms has voluntarily recalled its Mexico products containing shredded iceberg lettuce from 27 states, including Michigan — the epicenter of the outbreak, where over 6,100 people are believed to be infected — Florida, Texas, and North Carolina.

New York state is not currently one of them, so Whole Foods isn’t obligated to pull the products from its shelves (or at least as obligated as is possible under what is technically a voluntary recall). Still, the recall has been expanded at least once already, so it’s not impossible that it could include more states in the near future. A Whole Foods representative declined to go on record, but insisted that the bag of lettuce in question was sourced from the USA, not Mexico, adding that the chain doesn’t carry any of the recalled products.

Tracing the provenance of food products can be pretty byzantine. It’s not clear at this point if Taylor Farms supplied lettuce to companies in states affected by the recall who then distributed that lettuce again more widely, the New York Times noted. Not even the FDA has “distribution information or a list of customers who received” the recalled product since Taylor Farms hasn’t provided it, it said on its website — something it’s not legally required to do.

It’s even more confusing to the public. Taylor Farms doesn’t share which stores and restaurants it directly supplied its products too, so consumers have to do their own detective work, or rely on those locations voluntarily declaring that they used those products.

All that’s to say that there’s a lot of uncertainty over what lettuce is safe and what isn’t. The safest thing to do in this environment, probably, is to just abstain from shredded lettuce entirely. But you have to admit, isn’t that Whole Foods 50 percent discount tempting? Maybe if you’re used to paying outrageous prices for a bag of mushy leaves.

More on the outbreak: Taylor Farms Made Huge Donation to Trump Group After Loosening of Rules That Could Have Prevented Explosive Diarrhea Outbreak

The post Whole Foods Offering Steep Discount on Taylor Farms Shredded Iceberg Lettuce appeared first on Futurism.

In a stunning reversal on Sunday, the Food and Drug Administration said that lettuce samples from Taylor Farms did not, after all, test positive for the microscopic parasite Cyclospora cayetanensis, which is behind the rising outbreak of explosive diarrhea sweeping the nation.

Health officials have been racing to control the intestinal infection, which fortunately is not deadly, but can cause weeks of violently watery diarrhea.

By Saturday, the FDA said it had found traces of the parasite in shredded iceberg lettuce ⁠supplied by Taylor Farms — one of Taco Bell’s lead suppliers — only to change its mind just one day later.

“To be clear, at this moment, FDA has not identified a ​single positive product test result for cyclospora,” a Taylor Fresh Foods spokesperson told Reuters in a statement.

The bizarre 180 leaves far more questions than answers. And further muddying the waters was lawyer and public health policy leader Matthew Cortland’s stunning discovery about the food supplier’s relationship with the Trump administration.

In a post on Patreon, Cortland found that Taylor Farms had made a $1 million donation to the Trump-aligned super PAC MAGA Inc on March 26, 2025. That’s just six days after the FDA announced it was pushing back the implementation of its “Food Traceability Rule” by 30 months.

The rule, which was originally meant to go into effect on January 20 of this year, would’ve established “traceability recordkeeping requirements beyond those in existing regulations, for persons who manufacture, process, pack, or hold foods,” according to the regulator’s website.

Considering the effort would’ve allowed, in the words of the FDA, for the “faster identification and removal of potentially contaminated food from the market, resulting in fewer foodborne illnesses and deaths,” the agency’s decision to move back the compliance date raised eyebrows. (Congress even doubled down earlier this year, forbidding any funds to be appropriated to enforce the Food Traceability Rule before July 20, 2028.)

Where all of this leaves the ongoing outbreak of explosive diarrhea is tough to say. As Cortland points out, the Centers for Disease Control and Prevention has only acknowledged a small fraction of the cases of the illness so far. As of Friday, that’s 1,644 cases across five states. However, compared to reported tallies from individual states — Michigan alone has reported over 6,000 cases as of Monday — that’s likely vastly underestimating a more widespread phenomenon.

One reason for the discrepancy could be the difficulty of confirming the presence of the parasite with a lab test, a process that requires painstakingly dying eggs and then examining samples under a microscope. The parasite can’t be grown in a lab, greatly hampering scientists’ efforts to trace the outbreak.

“You’re looking for a needle in a haystack,” food-safety professional Jennifer McEntire, who consults for Taylor Fresh Foods, told the Wall Street Journal. “With E. coli and salmonella if you find it you can make the needle bigger. That doesn’t happen for cyclospora.”

Nonetheless, in terms of public health messaging, the ongoing outbreak is clearly causing far more confusion than it should, highlighting massive budget cuts that allow outbreaks like the current one to flourish.

And chances are that the situation could get even messier as the parasite spreads. The Trump administration’s FDA and USDA have lost tens of thousands of workers last year amidst budget cuts. A food surveillance program called FoodNet that monitored eight common foodborne pathogens is now no longer required to keep tabs on the cyclospora parasite. A team responsible for identifying parasitic outbreaks across the US was cut from 11 people to just three in September, as CNN reports.

For now, Taylor Fresh Foods will still have to recall its iceberg lettuce — despite the FDA now claiming the samples it viewed did not test positive after all.

More on the outbreak: Let’s Be Real, The Explosive Diarrhea Outbreak Is Trump’s Fault, Not Taco Bell’s

The post Taylor Farms Made Huge Donation to Trump Group After Loosening of Rules That Could Have Prevented Explosive Diarrhea Outbreak appeared first on Futurism.

In a new review paper, Dr. Gregory Marcus from the University of California, San Francisco and colleagues analyzed decades of research on how caffeine -- most often consumed as coffee -- affects the heart and its risk factors.

The post Moderate Coffee and Caffeine Intake Poses Little Heart Risk, and May Even Help appeared first on Sci.News: Breaking Science News.

The world has been obsessed with what Gen Z is or isn’t doing.  

They’re not having sex, apparently. They don’t go out. And let’s not forget drinking: for the young twenty-somethings to forgo damaging their livers and brains by imbibing poison as prolifically as their predecessors clearly shows a lack of respect — and that they don’t know anything about having a good time.

But it appears that in the end, the apple doesn’t fall too far from the tree. New research from beverage retail research group IWSR shows that Gen Z are now catching up on boozing like a friend knocking back a whole row of shots after showing up later than they said they would.

“They’re late to the party, they’re not skipping the party,” IWSR president Marten Lodewijks told Business Insider.

According to the survey, 74 percent of Gen-Zers say they’ve had at least one drink over the past six months, a huge leap from 66 percent just three three years ago. The heaviest drinkers were Millennials at 81 percent, and the lightest were Baby Boomers at 71 percent. Gen X, fittingly, were in the middle at 77 percent.

The legal drinking age youths are catching up, but their drinking habits look a little different from their elders’. They’re drinking more cocktails than any other generation, with 84 saying that they had a mixed drink in the past six months. Gen-Zers were also the most likely to follow government health guidance on alcohol (49 percent), and the most likely to say they drank alcohol with five or more people on their last occasion (18 percent).

In a statement, Lodewijks declared that Gen-Z’s reputation as the generation of moderation “is now conclusively debunked.”

“The evidence demonstrates that Gen Z consumers enjoy drinking at roughly the same levels as the rest of society,” he added.

In retrospect, it always should’ve been clear why Gen-Zers didn’t drink as much. Shifting attitudes towards drinking culture may be part of it, sure, but what almost certainly had the biggest part to say was the COVID-19 pandemic that stopped them from going out around when many of them just hit their legal drinking age.

“They were literally coming of age at a point in which everything got shut down,” Lodewijks told BI.

Wonderful. With their boozing now in line, what other Gen-Z habits can we worry about? Their addiction to romantic AI companions? We cast a mournful glance towards the bottle.

More on health habits: To Get Swole, Teens Are Pumping Themselves Full of Drugs Meant for Fattening Cows for the Slaughterhouse

The post Gen Z Appears to Be Reversing No-Drinking Trend, Now Lurching Toward Alcoholism appeared first on Futurism.